Literature DB >> 19658168

Structure and function of VEGF receptors.

Edward Stuttfeld1, Kurt Ballmer-Hofer.   

Abstract

Vascular endothelial growth factors (VEGFs) regulate blood and lymphatic vessel development and homeostasis. VEGFs are predominantly produced by endothelial, hematopoietic, and stromal cells in response to hypoxia and upon stimulation by growth factors such as transforming growth factor beta (TGFbeta), interleukins, or platelet-derived growth factors (PDGFs). VEGFs specifically interact with one or several receptor tyrosine kinases (RTKs), VEGF receptor-1, -2, and -3 (VEGFR-1, -2, -3), and with distinct coreceptors such as neuropilins or heparan sulfate glycosaminoglycans. VEGF receptors are classified as type V RTKs whose extracellular domains consists of seven immunoglobulin-like (Ig-like) domains. VEGF receptors are activated upon ligand-mediated dimerization. However, little was known about the mechanism of receptor activation at the structural level until recently. New data published by several labs for VEGF and the related type III RTKs now suggest that both ligand-receptor as well as homotypic receptor-receptor interactions stabilize ligand-induced receptor dimers. These data support the idea that structural changes induced in the extracellular domain upon ligand binding instigate transmembrane signaling by properly positioning the intracellular kinase domains in active receptor dimers. (c) 2009 IUBMB

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19658168     DOI: 10.1002/iub.234

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  61 in total

1.  Cloning and expression of soluble vascular endothelial growth factors receptor-1 (sFlt-1) fragments in CHO-K1.

Authors:  Poopak Farnia; Mojgan Bandehpour; Jalaledin Ghanavi; Bahram Kazemi
Journal:  Int J Clin Exp Med       Date:  2013-09-25

Review 2.  Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions.

Authors:  Prasanta K Hota; Matthias Buck
Journal:  Cell Mol Life Sci       Date:  2012-06-29       Impact factor: 9.261

Review 3.  Targeting extracellular domains D4 and D7 of vascular endothelial growth factor receptor 2 reveals allosteric receptor regulatory sites.

Authors:  Caroline A C Hyde; Alexandra Giese; Edward Stuttfeld; Johan Abram Saliba; Denis Villemagne; Thomas Schleier; H Kaspar Binz; Kurt Ballmer-Hofer
Journal:  Mol Cell Biol       Date:  2012-07-16       Impact factor: 4.272

4.  Annexin A8 promotes VEGF-A driven endothelial cell sprouting.

Authors:  Nicole Heitzig; Benjamin F Brinkmann; Sophia N Koerdt; Gonzalo Rosso; Victor Shahin; Ursula Rescher
Journal:  Cell Adh Migr       Date:  2017-01-06       Impact factor: 3.405

5.  Structural basis for VEGF-C binding to neuropilin-2 and sequestration by a soluble splice form.

Authors:  Matthew W Parker; Andrew D Linkugel; Hira Lal Goel; Tingting Wu; Arthur M Mercurio; Craig W Vander Kooi
Journal:  Structure       Date:  2015-03-05       Impact factor: 5.006

Review 6.  Atrial fibrillation: the role of hypoxia-inducible factor-1-regulated cytokines.

Authors:  Savalan Babapoor-Farrokhran; Deanna Gill; Jafar Alzubi; Sumeet K Mainigi
Journal:  Mol Cell Biochem       Date:  2021-02-11       Impact factor: 3.396

Review 7.  Manipulating the microvasculature and its microenvironment.

Authors:  Laxminarayanan Krishnan; Carlos C Chang; Sara S Nunes; Stuart K Williams; Jeffrey A Weiss; James B Hoying
Journal:  Crit Rev Biomed Eng       Date:  2013

Review 8.  Endothelial fatty acid transport: role of vascular endothelial growth factor B.

Authors:  Carolina Hagberg; Annika Mehlem; Annelie Falkevall; Lars Muhl; Ulf Eriksson
Journal:  Physiology (Bethesda)       Date:  2013-03

9.  Structural insights into the binding of vascular endothelial growth factor-B by VEGFR-1(D2): recognition and specificity.

Authors:  Shalini Iyer; Paula I Darley; K Ravi Acharya
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

10.  Met, IGF1R, and other new targets in upper GI malignancies.

Authors:  Elizabeta C Popa; Manish A Shah
Journal:  Curr Treat Options Oncol       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.